Catalyst Pharmaceuticals Statistics
Total Valuation
CPRX has a market cap or net worth of $2.85 billion. The enterprise value is $2.28 billion.
Important Dates
The last earnings date was Wednesday, May 7, 2025, after market close.
| Earnings Date | May 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CPRX has 121.98 million shares outstanding. The number of shares has increased by 8.38% in one year.
| Current Share Class | 121.98M |
| Shares Outstanding | 121.98M |
| Shares Change (YoY) | +8.38% |
| Shares Change (QoQ) | +0.54% |
| Owned by Insiders (%) | 7.47% |
| Owned by Institutions (%) | 79.95% |
| Float | 112.80M |
Valuation Ratios
The trailing PE ratio is 14.90 and the forward PE ratio is 14.48. CPRX's PEG ratio is 1.24.
| PE Ratio | 14.90 |
| Forward PE | 14.48 |
| PS Ratio | 5.09 |
| Forward PS | 5.06 |
| PB Ratio | 3.49 |
| P/TBV Ratio | 4.42 |
| P/FCF Ratio | 10.69 |
| P/OCF Ratio | 10.68 |
| PEG Ratio | 1.24 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 8.48, with an EV/FCF ratio of 8.53.
| EV / Earnings | 11.56 |
| EV / Sales | 4.27 |
| EV / EBITDA | 8.48 |
| EV / EBIT | 9.86 |
| EV / FCF | 8.53 |
Financial Position
The company has a current ratio of 6.14, with a Debt / Equity ratio of 0.00.
| Current Ratio | 6.14 |
| Quick Ratio | 5.84 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 29.11% and return on invested capital (ROIC) is 21.24%.
| Return on Equity (ROE) | 29.11% |
| Return on Assets (ROA) | 18.59% |
| Return on Invested Capital (ROIC) | 21.24% |
| Return on Capital Employed (ROCE) | 29.02% |
| Revenue Per Employee | $2.95M |
| Profits Per Employee | $1.09M |
| Employee Count | 181 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 3.83 |
Taxes
In the past 12 months, CPRX has paid $61.11 million in taxes.
| Income Tax | 61.11M |
| Effective Tax Rate | 23.64% |
Stock Price Statistics
The stock price has increased by +58.76% in the last 52 weeks. The beta is 0.70, so CPRX's price volatility has been lower than the market average.
| Beta (5Y) | 0.70 |
| 52-Week Price Change | +58.76% |
| 50-Day Moving Average | 23.00 |
| 200-Day Moving Average | 21.50 |
| Relative Strength Index (RSI) | 50.34 |
| Average Volume (20 Days) | 1,009,780 |
Short Selling Information
The latest short interest is 7.79 million, so 6.39% of the outstanding shares have been sold short.
| Short Interest | 7.79M |
| Short Previous Month | 7.93M |
| Short % of Shares Out | 6.39% |
| Short % of Float | 6.90% |
| Short Ratio (days to cover) | 4.70 |
Income Statement
In the last 12 months, CPRX had revenue of $534.65 million and earned $197.35 million in profits. Earnings per share was $1.57.
| Revenue | 534.65M |
| Gross Profit | 458.63M |
| Operating Income | 231.37M |
| Pretax Income | n/a |
| Net Income | 197.35M |
| EBITDA | 269.17M |
| EBIT | 231.37M |
| Earnings Per Share (EPS) | $1.57 |
Full Income StatementBalance Sheet
The company has $580.66 million in cash and $2.68 million in debt, giving a net cash position of $577.98 million or $4.74 per share.
| Cash & Cash Equivalents | 580.66M |
| Total Debt | 2.68M |
| Net Cash | 577.98M |
| Net Cash Per Share | $4.74 |
| Equity (Book Value) | 794.28M |
| Book Value Per Share | 6.51 |
| Working Capital | 574.07M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $267.93 million and capital expenditures -$357,000, giving a free cash flow of $267.57 million.
| Operating Cash Flow | 267.93M |
| Capital Expenditures | -357,000 |
| Free Cash Flow | 267.57M |
| FCF Per Share | $2.19 |
Full Cash Flow StatementMargins
Gross margin is 85.78%, with operating and profit margins of 43.27% and 36.91%.
| Gross Margin | 85.78% |
| Operating Margin | 43.27% |
| Pretax Margin | 48.34% |
| Profit Margin | 36.91% |
| EBITDA Margin | 50.35% |
| EBIT Margin | 43.27% |
| FCF Margin | 50.05% |